Board of Directors of Ozon Pharmaceuticals approved the sale of 12,927,030 quasi-treasury shares of the company, which make up 1.1% of the authorized capital. Management plans to gradually sell shares to the market during 2025 and 2026 with minimal impact on the quotation.